EcoDrugPlus

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSUPAG00010007041
Gene Symbol: HTR2C
3 Cross references
226 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSUPAG00010021143
Gene Symbol: HTR3A
3 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSUPAG00010021131
Gene Symbol: HTR3B
3 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSUPAG00010013156
Gene Symbol: HTR4
1 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSUPAG00010012226
Gene Symbol: HTR5A
3 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSUPAG00010013487
Gene Symbol: HTR6
3 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSUPAG00010011303
Gene Symbol: HTR7
3 Cross references
219 Possible Orthologues:

60s Ribosomal Protein L27

Ensembl ID : ENSUPAG00010002680
Gene Symbol: LOC113196418
2 Cross references
197 Possible Orthologues:

60s Ribosomal Protein L27

Ensembl ID : ENSUPAG00010010297
Gene Symbol: LOC113196418
2 Cross references
197 Possible Orthologues:

60s Ribosomal Protein L30-Like

Ensembl ID : ENSUPAG00010013235
Gene Symbol: LOC113181783
2 Cross references
319 Possible Orthologues:

60s Ribosomal Protein L7

Ensembl ID : ENSUPAG00010001674
Gene Symbol: LOC113196977
2 Cross references
194 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSUPAG00010017102
Gene Symbol: ARAF
1 Cross references
191 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).